Systemair’s Q1 report was in line with our estimates on all major accounts.
Redeye provides a research update on Faron following the company’s recent H1 report.
Redeye comments briefly on Sleep Cycle's decision to appoint CTPO Mikael Kågeback as acting CEO in p...
Redeye provides a review following AcouSort's Q2 2026 report, which, apart from slight deviations fr...
Enviro has taken an important step towards exiting its financial restructuring, with a proposed 30% ...
SynAct’s Q226 results marked a strategically important period in defining resomelagon’s clinical and...
Stark tillväxt men svagare lönsamhet än väntat Nettoomsättningen ökade med 34,1 % till 183,0 MSEK (...
Redeye comments on Fable Media Group's Q2 2026 results, bang in line with our estimates across the b...
Redeye provides its first take on Oncopeptides' Q2 report 2026.
Redeye updates on Gentoo Media after Q2-results which were weaker than expected as topline continued...
Redeye notes that Smart Eye's Q2 was softer than expected, with Automotive missing on what we believ...
Redeye returns with updated estimates and valuation following Sleep Cycle's Q2 2026 report, presenta...
Redeye provides an update following Corline’s Q2 2026 report.
InfraCom missed on both net sales and EBITA in Q2 2026 against an easy comparable.
Prospekterings- och gruvutvecklingsbolaget Bluelake Mineral har erhållit de första resultaten från d...
Mendus’s Q226 results highlighted continued execution of its broadened vididencel strategy, with the...
Rekryteringen av patienter till tasquinimod-studien i USA har gått trögare än väntat och bolaget bre...
Redeye notes that Smart Eye's Q2 2026 report fell short of our expectations, with the miss driven en...
* Q2 adj. EBITDA 19% below FactSet consensus * '26 adj.
InfraCom’s Q2 2026 report fell short of expectations against an easy comparable, with net sales grow...